AU2001270157A1 - Rapid and sensitive detection of protein aggregation - Google Patents

Rapid and sensitive detection of protein aggregation

Info

Publication number
AU2001270157A1
AU2001270157A1 AU2001270157A AU7015701A AU2001270157A1 AU 2001270157 A1 AU2001270157 A1 AU 2001270157A1 AU 2001270157 A AU2001270157 A AU 2001270157A AU 7015701 A AU7015701 A AU 7015701A AU 2001270157 A1 AU2001270157 A1 AU 2001270157A1
Authority
AU
Australia
Prior art keywords
species
binding
aggregate
forming
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270157A
Other languages
English (en)
Inventor
Cynthia C. Bamdad
R. Shoshana Bamdad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of AU2001270157A1 publication Critical patent/AU2001270157A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Materials Engineering (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Composite Materials (AREA)
AU2001270157A 1999-01-25 2001-06-25 Rapid and sensitive detection of protein aggregation Abandoned AU2001270157A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US60117126 1999-01-25
US60132288 1999-05-03
US60155937 1999-09-24
US60268900A 2000-06-23 2000-06-23
US09602689 2000-06-23
US63181800A 2000-08-03 2000-08-03
US09631818 2000-08-03
PCT/US2001/020232 WO2002001230A2 (en) 2000-06-23 2001-06-25 Rapid and sensitive detection of protein aggregation

Publications (1)

Publication Number Publication Date
AU2001270157A1 true AU2001270157A1 (en) 2002-01-08

Family

ID=27084216

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001270157A Abandoned AU2001270157A1 (en) 1999-01-25 2001-06-25 Rapid and sensitive detection of protein aggregation

Country Status (5)

Country Link
EP (1) EP1356296B1 (ja)
JP (4) JP2004526124A (ja)
AU (1) AU2001270157A1 (ja)
CA (1) CA2413884A1 (ja)
WO (1) WO2002001230A2 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004526124A (ja) * 2000-06-23 2004-08-26 ミナーヴァ・バイオテクノロジーズ・コーポレーション タンパク質凝集の迅速且つ高感度の検出
AU2002216614A1 (en) 2000-10-03 2002-04-15 Minerva Biotechnologies Corporation Electronic detection of interaction based on the interruption of flow
ATE426807T1 (de) * 2000-11-01 2009-04-15 Minerva Biotechnologies Corp Proteomanalyse verfahren zum drogen vergleich
JP4568840B2 (ja) * 2004-12-28 2010-10-27 国立大学法人金沢大学 アルツハイマー病の検査方法
JP5164971B2 (ja) * 2006-04-21 2013-03-21 ピープルバイオ，アイ エヌ シー 三次元的相互作用を用いてマルチマー形成ポリペプチドのモノマーからマルチマーを分別検出する方法
JP2008032554A (ja) * 2006-07-28 2008-02-14 Japan Science & Technology Agency βアミロイドオリゴマーを用いたバイオチップおよびアミロイドセンサーならびに生体試料中に存在するβアミロイドの検出方法
JP4969236B2 (ja) * 2006-12-22 2012-07-04 ローム株式会社 生体分子または生体関連物質の測定方法
EP2300032A4 (en) 2008-05-13 2012-12-05 Univ Kansas MARKER PRESENTING IN THE FORM OF A MAP PEPTIDE (METAL ABSTRACTION PEPTIDE) AND ASSOCIATED METHODS
US20140213465A1 (en) * 2011-12-02 2014-07-31 Plaxgen, Inc. Plaque array methods and compositions for forming and detecting plaques
JP5205293B2 (ja) * 2009-01-19 2013-06-05 富士フイルム株式会社 抗体固定基板、並びに該抗体固定基板の製造方法及び利用
CA2753586A1 (en) * 2009-02-24 2010-09-02 Winton G. Gibbons Detection of complexes of tau and amyloid
WO2011049530A1 (en) * 2009-10-23 2011-04-28 Ge Healthcare Bio-Sciences Ab Method for determination of macromolecular multimers
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
KR101448353B1 (ko) 2012-09-24 2014-10-10 한양대학교 산학협력단 단백질분해효소 활성 분석 방법 및 그 응용
KR101451797B1 (ko) 2012-11-07 2014-10-16 가천대학교 산학협력단 멀티머-형성 폴리펩타이드의 멀티머 정량분석을 위한 표준 단백질 복합체
WO2015159534A1 (ja) * 2014-04-16 2015-10-22 富士フイルム株式会社 検出液及びそれを用いたバイオセンシング方法
DE102015003404B4 (de) * 2015-03-18 2021-10-07 Forschungszentrum Jülich GmbH Verfahren zur Herstellung eines Standards für den Nachweis von Proteinaggregaten einer Proteinfehlfaltungserkrankung sowie Standard und dessen Verwendung
US20180299399A1 (en) * 2015-10-14 2018-10-18 University Health Network Electrochemical assay for a protein analyte
JP2019533636A (ja) * 2016-08-05 2019-11-21 深▲セン▼深見医薬科技有限公司Ｓｈｅｎｚｈｅｎ Ｐｒｏｆｏｕｎｄ−Ｖｉｅｗ Ｐｈａｒｍａ Ｔｅｃｈ Ｃｏ．， Ｌｔｄ． ＡｕＣ含有物質、並びにその製造方法及びその使用
CN113748192B (zh) 2019-04-12 2023-08-29 埃科莱布美国股份有限公司 抗微生物多用途清洁剂及其制备和使用方法
KR102489239B1 (ko) * 2019-10-15 2023-01-17 고려대학교 산학협력단 단백질 응집체 검출용 형광 프로브 화합물 및 이를 포함하는 단백질 응집체 검출용 형광 센서

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0750112B2 (ja) * 1988-04-26 1995-05-31 日本電信電話株式会社 レーザ磁気免疫測定方法を実施するための検体調整方法
IL85137A (en) * 1987-01-21 1992-02-16 Ares Serono Res & Dev Ltd Method of assaying for a ligand using surface plasmon resonance effect
US5294369A (en) * 1990-12-05 1994-03-15 Akzo N.V. Ligand gold bonding
US5369036A (en) * 1992-07-02 1994-11-29 Becton, Dickinson And Company Enhancement of signal in immunoassays using microparticles which contain different detectable substances
US5935927A (en) * 1994-02-03 1999-08-10 The Picower Institute For Medical Research Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
US5620850A (en) * 1994-09-26 1997-04-15 President And Fellows Of Harvard College Molecular recognition at surfaces derivatized with self-assembled monolayers
US6306584B1 (en) * 1997-01-21 2001-10-23 President And Fellows Of Harvard College Electronic-property probing of biological molecules at surfaces
AU6174098A (en) * 1997-02-19 1998-09-09 President And Fellows Of Harvard College Abeta deposition inhibitor screen using synthetic amyloid
DE19715483A1 (de) * 1997-04-14 1998-10-15 Boehringer Mannheim Gmbh Methode zur gleichzeitigen Bestimmung von biomolekularen Wechselwirkungen mittels Plasmonenresonanz undFluoreszenzdetektion
JPH1132764A (ja) * 1997-07-14 1999-02-09 Yakult Honsha Co Ltd ビフィドバクテリウム・ブレーベ用モノクローナル抗体
AU743905B2 (en) * 1997-08-14 2002-02-07 Regents Of The University Of California, The Fluorescent amyloid abeta peptides and uses thereof
US6541617B1 (en) * 1998-10-27 2003-04-01 Clinical Micro Sensors, Inc. Detection of target analytes using particles and electrodes
AU3474100A (en) * 1999-01-25 2000-08-07 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
JP2004526124A (ja) * 2000-06-23 2004-08-26 ミナーヴァ・バイオテクノロジーズ・コーポレーション タンパク質凝集の迅速且つ高感度の検出

Also Published As

Publication number Publication date
JP2015096855A (ja) 2015-05-21
CA2413884A1 (en) 2002-01-03
EP1356296A2 (en) 2003-10-29
EP1356296B1 (en) 2016-04-20
JP2017122728A (ja) 2017-07-13
JP6662797B2 (ja) 2020-03-11
WO2002001230A2 (en) 2002-01-03
JP2014013242A (ja) 2014-01-23
JP2004526124A (ja) 2004-08-26
WO2002001230A3 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
JP6662797B2 (ja) タンパク質凝集の迅速且つ高感度の検出
EP1169646A2 (en) Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
US20050112607A1 (en) Rapid and sensitive detection of protein aggregation
CA2423630C (en) Magnetic in situ dilution
JP5466029B2 (ja) オリゴヌクレオチド識別子
AU2001296579A1 (en) Magnetic in situ dilution
EP2320231A2 (en) Assays involving sam-modified colloids and non-colloidal structures
US20050148101A1 (en) Interaction of colloid-immobilized species with species on non-colloidal structures
CA2413932A1 (en) Interaction of colloid-immobilized species with species on non-colloidal structures
US20060024230A1 (en) Customized therapeutics and in situ diagnostics
US20050202402A1 (en) Tandem signaling assay
AU2001270140A1 (en) Interaction of colloid-immobilized species with species on non-colloidal structures
AU2002248159A1 (en) Oligonucleotide identifiers